- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05870787
iMproving thE DIagnostics And Treatment Of ceRvical Precancer (MEDIATOR)
Cervical cancer screening is important as it enables identification of women at increased risk of the disease, but high-quality diagnostics of screen-positive women and effective treatment of those with precancer are critical in preventing progression to cancer. With the current transition from cytology-based to primary human papillomavirus (HPV)-screening and a growing proportion of HPV-vaccinated women, diagnostics of screen-positive women will become more challenging in the decades to come. Thus, there is a need to explore how to improve diagnostics while ensuring a low number of unnecessary procedures such as colposcopy and the collection of multiple cervical biopsies.
The overall purpose is:
- To investigate the diagnostic accuracy of cervical precancer when using a colposcopic scoring system in the diagnostic work-up of screen-positive women.
- To investigate the performance of a colposcopic scoring system to identify women without cervical precancer in whom collection of biopsies can be safely omitted.
Study Overview
Status
Intervention / Treatment
Detailed Description
Introduction Cervical cancer is the fourth most common cancer in women worldwide. Every year, 375 women are diagnosed with cervical cancer in Denmark, and approximately 90 women die from the disease. Cervical cancer is caused by the sexually transmitted virus, human papillomavirus (HPV). When infected about 85-90 % clear the virus within a year or two. The remaining women develop a persistent HPV infection, which is associated with an increased risk of cervical intraepithelial neoplasia (CIN), which may progress to cancer if left untreated. Cervical cancer can be prevented through prophylactic HPV vaccination and screening. In Denmark, women aged 23 - 64 years are invited to the screening program. Women who do not participate in regular screening have an increased risk of cervical cancer, however up to 55% of cervical cancers are diagnosed in women who have attended screening. Hence, the performance of diagnostics is crucial.
Diagnostics Women with abnormal screening results may undergo repeat testing or be referred for colposcopy. Colposcopy allows the colposcopist to magnify and visualize the cervix with the transformation zone, where cervical cancer and cervical lesions typically arise. The aim is to make a colposcopic diagnosis and select the most severe area for biopsies, which undergo histopathological examination. Studies have shown considerable inter- and intra-observer variability even among experienced colposcopists, and a variable sensitivity of colposcopy as low as 55-57%. These findings suggest a need to improve the detection rate of CIN2+. A validated colposcopic scoring system, the Swede score, has been designed to improve the detection of high-grade cervical lesions, specified as cervical intraepithelial neoplasia grade 2 or worse (CIN2+) by providing an systematic approach to the colposcopy examination. The Swede score includes five variables (degree of 1) acetowhitening, 2) margins and surface, 3) vessels, 4) lesion size, and 5) iodine staining by using Lugols iodine) with a score from 0 - 2. Conventional colposcopy only utilizes acetic acid. In the original study, the Swede score had a high sensitivity and specificity for detecting high-grade cervical lesions (CIN2+), with an area under the receiver operating characteristics (ROC) curve of 0.87. Even so, the Swede score is endorsed by the International Agency for Research on Cancer (IARC/WHO) and by the European Federation for Colposcopy (EFC), it has not yet been implemented in Denmark. As previous studies have mostly evaluated the use of the Swede score among expert colposcopists, it is important to assess whether the score may be a valuable tool among non-experts. In Denmark, colposcopy is mostly performed by non-experts gynecologists. As a result of the low performance of colposcopy, and because several studies have shown that the CIN2+ detection rate increases with the number of biopsies collected, the Danish national guidelines recommend that all women should have a minimum of 4 biopsies collected. Biopsies should be collected from abnormal areas of the cervix and, if no lesion is detected, random biopsies should be taken. Our neighboring Scandinavian countries, for example Sweden and Finland, do not recommend collection of random biopsies. If biopsies could be omitted without increasing the risk of missing disease and reducing the harms with pain, bleeding and discomfort, this would benefit the women.
Aim The project aims to explore whether the implementation of a systematic colposcopic scoring system, the Swede score, can improve diagnostic accuracy of cervical lesions with detection of CIN2+ in a Danish clinical setting. Furthermore, we want to evaluate whether the Swede score can be used to assess when random biopsies can be safely omitted.
Data Characteristics of the women will be collected from medical records (previous gynecological historic, parity, smoking status, HPV-vaccination status, hormone use or immunosuppressive treatment). From the Danish Pathology Databank, we will collect data on previous screening history, result of the referral screening test, result of current and subsequent cervical biopsies and/or cervical excision.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ane-Kersti Knudsen, MD,Ph.d.stud
- Phone Number: +78430000
- Email: ane.kersti@midt.rm.dk
Study Locations
-
-
-
Fredericia, Denmark, 7000
- Recruiting
- Guldberg Kvindeklinik
-
Contact:
- Rikke Guldberg
- Phone Number: +4575806480
- Email: rguldberg@dadlnet.dk
-
Herning, Denmark, 7400
- Recruiting
- Gødstrup Regional Hospital
-
Contact:
- Anne Hammer
- Phone Number: +23494736
- Email: ahlauridsen@clin.au.dk
-
Horsens, Denmark, 8700
- Recruiting
- Horsens Regional Hospital
-
Contact:
- Christina Blach
- Phone Number: +457842 6444
- Email: chissore@rm.dk
-
Horsens, Denmark, 8700
- Recruiting
- Horsens Gynækologisk Klinik
-
Contact:
- Helene Nortvig
- Phone Number: +4575614808
- Email: nortvig@dadlnet.dk
-
Odense, Denmark, 5000
- Not yet recruiting
- Odense Univeristy Hospital
-
Contact:
- Lone Kjeld Petersen
- Phone Number: +4530576810
- Email: Lone.Kjeld.Petersen@rsyd.dk
-
Randers, Denmark, 8900
- Recruiting
- Randers Regional Hospital
-
Contact:
- Eva Hauge
- Phone Number: +4578421114
- Email: evahauge@rm.dk
-
Viborg, Denmark, 8800
- Recruiting
- Viborg Regional Hospital
-
Contact:
- Attila Botházi
- Phone Number: +45 78445865
- Email: attiboth@rm.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women referred to colposcopy due to abnormal smear (HPV-genotype and cytology) in Central Denmark Region or Southern Denmark Region.
Exclusion Criteria:
- Allergic to iodine.
- Tranformationzone not visible (type 3).
- Atrophy of cervical epithelium.
- Women referred to colposcopy with no cervical biopsies taken or invalid cervical biopsies.
- Women with previous cone biopsy, hysterectomy or without a cervix due to cervical cancer will be excluded.
- Pregnant women.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Swede score colposcopy
Swede score colposcopy: includes application with acetic acid, supplemented with a systematic scoring system (the Swede score) including Lugols iodine, and collection of cervical biopsies.
|
New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
|
Conventional colposcopy
Conventional colposcopy: includes application with acetic acid and collection of cervical biopsies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnosis of collected cervical biopsies
Time Frame: When the histological report is available - typically within 12 weeks after the biopsy was taken
|
The number of women diagnosed with Cervical Intraepithelial Neoplasia grade 2 or worse (CIN2+) diagnosed in cervical biopsies
|
When the histological report is available - typically within 12 weeks after the biopsy was taken
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Anne Hammer, MD, as.prof, University of Aarhus
- Study Chair: Ulrik Schiøler Kesmodel, MD, prof, Aalborg University Hospital
- Study Chair: Line Winther Gustafson, MD, Ph.d., Aarhus University Hospital
- Study Chair: Berit Bargum Booth, MD, Ph.d., Randers Regional Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Precancerous Conditions
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Uterine Cervical Dysplasia
- Uterine Cervical Diseases
Other Study ID Numbers
- 2022-0367531-3031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on Swede score colposcopy
-
Zydolab - Institute of Cytology and Immune CytochemistryRuhr University of BochumCompleted
-
General University Hospital, PragueRecruitingHPV | CIN2 | CIN3 | Cervix Uteri SILCzechia
-
Bezmialem Vakif UniversityCompletedHuman Papillomavirus Infection
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCervical CancerUnited States, Canada, Nigeria
-
Zydolab - Institute of Cytology and Immune CytochemistryCompleted
-
Ruhr University of BochumCompletedPain | Anxiety | Cervical DysplasiaGermany
-
Université de MontréalCompletedJaw, EdentulousCanada
-
University Hospital, Strasbourg, FranceUnknownCervical Intraepithelial Neoplasia Grade 1 (CIN 1)France
-
Karolinska InstitutetKarolinska University Hospital; Regional Cancer Centre Stockholm GotlandEnrolling by invitationUterine Cervical CancerSweden
-
Preventive Oncology International, Inc.Peking University Shenzhen HospitalCompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Human Papillomavirus | Cervical Dysplasia | Cervical NeoplasmChina